Erich Bluhmki

43.2k citations

81 papers · 24.3k indexed · 7 hit papers · h-index 42

Impact in

Internal Medicine top 0.05%
- Venous Thromboembolism Diagnosis and Management
Rehabilitation top 0.01%
- Stroke Rehabilitation and Recovery

Papers in

Internal Medicine 21
- Venous Thromboembolism Diagnosis and Management 21
Rehabilitation 15
- Stroke Rehabilitation and Recovery 15

Co-authors: Rüdiger von Kummer Werner Hacke Vincent Larrue John M. Lachin Bernard Zinman Markku Kaste Odd Erik Johansen Christoph Wanner
Journals: Stroke (15 papers)Lara D. Veeken (7 papers)International Journal of Stroke (6 papers)American Heart Journal (4 papers)New England Journal of Medicine (3 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Erich Bluhmki

79 papers receiving 23.5k citations

Hit Papers

7 papers align trajectories log scale

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial 2017 · 526 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Diabetes Care
2015 New England Journal of Medicine
2010 The Lancet
2008 New England Journal of Medicine
2001 Stroke
1998 The Lancet
1995 PubMed

Peers

Countries citing papers authored by Erich Bluhmki

Since Specialization

Citations

This map shows the geographic impact of Erich Bluhmki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erich Bluhmki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erich Bluhmki more than expected).

Fields of papers citing papers by Erich Bluhmki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erich Bluhmki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erich Bluhmki. The network helps show where Erich Bluhmki may publish in the future.

Co-authors

The 25 scholars most cited alongside Erich Bluhmki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Erich Bluhmki Line = papers co-authored together Erich Bluhmki links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Solubilization of inclusion bodies: insights from explainable machine learning approaches SHILAP Revista de lepidopterología ·Cornelia Walther, Michael C. Martinetz, Anja Friedrich, Anne-Luise Tscheließnig, Martin Voigtmann, Alexander Jung, Cécile Brocard, Erich Bluhmki, Jens Smiatek	2023	3
2	Comparison of nonparametric estimators of the expected number of recurrent events Pharmaceutical Statistics ·Alexandra Erdmann, Jan Beyersmann, Erich Bluhmki	2023	0
3	Asymptotic properties of the two one-sided t -tests – new insights and the Schuirmann-constant The International Journal of Biostatistics ·Christian Palmes, Tobias Bluhmki, Benedikt Funke, Erich Bluhmki	2021	1
4	Generic and specific recurrent neural network models: Applications for large and small scale biopharmaceutical upstream processes Biotechnology Reports ·Jens Smiatek, Christoph Clemens, Liliana Montano-Herrera, Sabine Arnold, Bettina L. Knapp, Beate Presser, Alexander Jung, Thomas Wucherpfennig, Erich Bluhmki	2021	22
5	Mediators of the Improvement in Heart Failure Outcomes with Empagliflozin in the EMPA-REG OUTCOME Trial ESC Heart Failure ·David Fitchett, Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Anne Pernille Ofstad, Afshin Salsali, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin, Faı̈ez Zannad	2021	61
6	Artificial neural networks for the prediction of solvation energies based on experimental and computational data Physical Chemistry Chemical Physics ·Jiyoung Yang, Matthias J. Knape, Oliver Burkert, Virginia Mazzini, Alexander Jung, Vincent S. J. Craig, Ramón Alain Miranda‐Quintana, Erich Bluhmki, Jens Smiatek	2020	15
7	Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial American Heart Journal ·Paul W. Armstrong, Yinggan Zheng, Cynthia M. Westerhout, Fernando Rosell Ortiz, Peter Sinnaeve, Yves Lambert, Renato D. Lópes, Erich Bluhmki, Thierry Danays, Frans Van de Werf	2015	15
8	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) Cardiovascular Diabetology ·Bernard Zinman, Silvio E. Inzucchi, John M. Lachin, Christoph Wanner, Roberto Ferrari, David Fitchett, Erich Bluhmki, Stefan Hantel, Joan Kempthorne‐Rawson, Jennifer Newman, Odd Erik Johansen, Hans‐Juergen Woerle, Uli C. Broedl	2014	173
9	Influence of Age on Outcome From Thrombolysis in Acute Stroke Stroke ·Nishant K. Mishra, Hans‐Christoph Diener, Patrick D. Lyden, Erich Bluhmki, Kennedy R. Lees	2010	72
10	Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials The Lancet ·Kennedy R. Lees, Erich Bluhmki, Rüdiger von Kummer, Thomas Brott, Danilo Toni, James C. Grotta, Gregory W. Albers, Markku Kaste, John R. Marler, Scott Hamilton, (unknown), Stephen M. Davis, Geoffrey A. Donnan, Werner Hacke Hit paper breakdown →	2010	1570
11	Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale Stroke ·Maarten G. Lansberg, Maarten Schrooten, Erich Bluhmki, Vincent Thijs, Jeffrey L. Saver	2009	152
12	Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial The Lancet Neurology ·Erich Bluhmki, Ángel Chamorro, Antoni Dávalos, Thomas Machnig, Christophe Sauce, Nils Wahlgren, Joanna M. Wardlaw, Werner Hacke	2009	266
13	Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials Stroke ·Nils Wahlgren, Niaz Ahmed, Niclas Eriksson, F. Aichner, Erich Bluhmki, Antoni Dávalos, T. Erilä, Gary A. Ford, Martin Grond, Werner Hacke, Michael G. Hennerici, Markku Kaste, Martin Köhrmann, Vincent Larrue, Kennedy R. Lees, Thomas Machnig, Risto O. Roine, Danilo Toni, Geert Vanhooren	2008	335
14	Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients Inflammation Research ·Bernard Combe, Patrick Vélicitat, Nelson Adolfo López Garzón, Erich Bluhmki	2001	16
15	Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial American Heart Journal ·Frans Van de Werf, Christopher P. Cannon, Anne Luyten, Katrijn Houbracken, Carolyn H. McCabe, S Berioli, Erich Bluhmki, H. SARELIN, F Wang-Clow, Norma Lynn Fox, Eugene Braunwald	1999	111
16	The ECASS 3-Hour Cohort Cerebrovascular Diseases ·Thorsten Steiner, Erich Bluhmki, Markku Kaste, Danilo Toni, P Trouillas, Rüdiger von Kummer, Werner Hacke	1998	86
17	Efficacy and safety of meloxicam in patients with rheumatoid arthritis. PubMed ·E.‐M. Lemmel, W. Bolten, Rubén Burgos‐Vargas, Philip Platt, M. Nissilä, Dick Sahlberg, Olav Bjørneboe, Heiko Baumgartner, J P Valat, P Franchimont, Erich Bluhmki, Gertraud Hanft, M. Distel	1997	35
18	Evaluation of the safety, tolerability, and efficacy of meloxicam tablets in patients with osteoarthritis Clinical Therapeutics ·P. Prouse, Peter J.R. Bevis, Erich Bluhmki, M. Distel	1996	9
19	Tolerability of Multiple Administration of Intramuscular Meloxicam: A Comparison with Intramuscular Piroxicam in Patients with Rheumatoid Arthritis or Osteoarthritis Lara D. Veeken ·P. R. Ghozlan, M. Brooke Bernhardt, Patrick Vélicitat, Erich Bluhmki	1996	20
20	Calculation of power and sample size with bounded outcome scores Statistics in Medicine ·Emmanuel Lesaffre, Ilse Scheys, Jürgen Fröhlich, Erich Bluhmki	1993	25

About Erich Bluhmki

Erich Bluhmki is a scholar working on Internal Medicine, Rehabilitation, Epidemiology, Statistics and Probability and Pharmacology, having authored 81 papers that have together received 24.3k indexed citations. Recurring topics across this work include Acute Ischemic Stroke Management (35 papers), Venous Thromboembolism Diagnosis and Management (21 papers), Stroke Rehabilitation and Recovery (15 papers), Inflammatory mediators and NSAID effects (13 papers), Drug-Induced Adverse Reactions (9 papers), Cerebrovascular and Carotid Artery Diseases (9 papers), Diabetes Treatment and Management (8 papers) and Acute Myocardial Infarction Research (7 papers). The work is most often cited by research in Internal Medicine (4.4k citations), Rehabilitation (4.4k citations), Endocrinology, Diabetes and Metabolism (7.8k citations), Epidemiology (12.9k citations) and Neurology (5.1k citations). Erich Bluhmki has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Rüdiger von Kummer, Werner Hacke, Vincent Larrue, John M. Lachin, Bernard Zinman, Markku Kaste, Odd Erik Johansen, Christoph Wanner, Silvio E. Inzucchi and Stefan Hantel. Their work appears in journals such as Stroke, Lara D. Veeken, International Journal of Stroke, American Heart Journal and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact